The Tevogen Bio Holdings Inc. (TVGN) SEC filings page on Stock Titan aggregates the company’s official disclosures from the U.S. Securities and Exchange Commission, offering a structured view into this clinical-stage biotechnology issuer’s regulatory record. As a Nasdaq-listed company, Tevogen files periodic reports and current reports that detail its financial performance, operating strategy, and material events.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include audited or reviewed financial statements, management’s discussion and analysis, and commentary on Tevogen’s capital-efficient, cost-disciplined business model. For a company focused on precision T cell therapies and AI-enabled drug discovery, these filings provide context on research and development spending, general and administrative expenses, and non-GAAP measures such as adjusted loss from operations that Tevogen uses to describe operational performance.
Current reports on Form 8-K capture significant events, including listing and compliance matters. For example, Tevogen disclosed via Form 8-K that it received a Nasdaq notice regarding non-compliance with the $1.00 per share minimum bid price requirement, outlining the applicable compliance period and potential paths to regain compliance. Such filings help investors understand listing status and associated timelines.
The filings page also offers access to information related to equity structure, warrants, and other securities, as well as any proxy materials and, where applicable, insider transaction reports on Form 4. Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify items such as changes in operating loss, capital structure, or risk disclosures. Real-time updates from EDGAR ensure that new TVGN filings, from 10-Qs to 8-Ks, appear promptly with accessible explanations for investors analyzing Tevogen’s financial and regulatory trajectory.
Tevogen Inc. (TVGN) regained compliance with the $50 million minimum market value of listed securities requirement for continued listing on The Nasdaq Global Market after receiving Nasdaq’s written notice on September 29, 2026.
Tevogen had also regained compliance with the minimum market value of publicly held shares requirement on September 9, 2026. With both requirements satisfied, the related Nasdaq compliance matters are closed.
Tevogen Inc. (TVGN) reports that Ryan H. Saadi beneficially owns 11,709,567 shares of its common stock, representing 74.4% of 15,736,540 shares outstanding as of September 14, 2026. This includes 9,766,979 shares of restricted common stock that are outstanding with voting rights but are non‑transferable and subject to forfeiture.
On September 14, 2026, Tevogen Inc. granted Dr. Saadi 8,000,000 restricted shares under the 2024 Omnibus Incentive Plan. These shares vest only if the company achieves $1.0 billion in aggregate revenue during the period from September 14, 2026 through September 30, 2031, and are otherwise subject to various forfeiture conditions, including certain termination events, misconduct, competitive activities, transfer attempts before vesting, or non‑assumption in a change in control.
Tevogen Inc. (TVGN) received an amended Schedule 13D from shareholder Kirti Desai reflecting a new performance-based equity award. Desai now beneficially owns 992,983 shares of Common Stock, representing 6.3% of the class, based on 15,736,540 shares outstanding as of September 14, 2026. This total includes 805,000 shares of restricted Common Stock that carry voting rights but are subject to transfer restrictions and potential forfeiture. On September 14, 2026, Tevogen granted Desai 750,000 restricted Common Stock shares under the 2024 Omnibus Incentive Plan, which vest only if the Board certifies that the Company achieves $1.0 billion in aggregate revenue during the period from September 14, 2026 through September 30, 2031. The award is subject to forfeiture if the revenue threshold is not met, upon termination of service, certain misconduct or competitive activities, prohibited transfers, or if the award is not assumed in a change in control.
Tevogen Inc. (symbol: TVGN) is the issuer of record for a Form 4 filing submitted to the SEC. Saadi Ryan H. reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Inc. (TVGN) reported that Chief Executive Officer and director Ryan H. Saadi received a grant of 8,000,000 shares of restricted common stock on September 14, 2026. According to the award terms, these shares vest only if the Board certifies that Tevogen achieves $1.0 billion in aggregate revenue during the period from September 14, 2026 through September 30, 2031, and are subject to automatic forfeiture if this performance condition or continued service and other conditions are not met. Following this grant, Saadi directly holds 11,705,689 common shares, and he is also reported as indirectly owning 3,878 shares held by his wife. No transactions are reported under a Rule 10b5-1 trading plan.
Tevogen Inc. (symbol: TVGN) is the issuer of record for a Form 4 filing submitted to the SEC. Desai Kirti reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Inc. (TVGN) reported that its Chief Financial Officer, Kirti Desai, received a grant of 750,000 shares of restricted common stock on September 14, 2026. These shares vest only if the company achieves $1.0 billion in aggregate revenue during the period from September 14, 2026 through September 30, 2031, and are otherwise subject to forfeiture under specified conditions. Following this award, Desai holds 992,983 shares of common stock directly.
Tevogen Inc. (TVGN) reported granting performance-based restricted stock awards on September 14, 2026 to its top executives under the 2024 Omnibus Incentive Plan. Chief Executive Officer Ryan Saadi received 8,000,000 restricted shares and Chief Financial Officer Kirti Desai received 750,000 restricted shares of common stock.
The awards vest only if the Board certifies achievement of $1.0 billion in aggregate revenue by September 30, 2031; until then, the shares are non-transferable but carry voting rights. Immediately after the grant, Saadi owned 74.4% and Desai owned 6.3% of 15,736,540 outstanding common shares, aligning their potential realized compensation with long-term revenue growth.
Tevogen Inc. (symbol: TVGN) is the issuer of record for a Form 4 filing submitted to the SEC. Goh Keow Lin reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Inc. (TVGN) reported that director Goh Keow Lin received a grant of 75,000 shares of restricted common stock on September 11, 2026 under the Tevogen Inc. 2024 Omnibus Incentive Plan. The award vests in three equal annual installments starting September 11, 2027, conditional on continued service, bringing the director’s direct holdings to 123,678 shares.
Tevogen Inc. (symbol: TVGN) is the issuer of record for a Form 4 filing submitted to the SEC. PODLOGAR SUSAN M reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Inc. (TVGN) reported that director Susan M. Podlogar received a grant of 75,000 shares of Common Stock as restricted stock on September 11, 2026 under the Tevogen Inc. 2024 Omnibus Incentive Plan. These shares will vest ratably in three equal annual installments starting September 11, 2027, contingent on continued service, leaving her with 123,678 shares of common stock held directly after the grant. No Rule 10b5-1 trading plan is reported.
Tevogen Inc. (symbol: TVGN) is the issuer of record for a Form 4 filing submitted to the SEC. Sordillo Victor J. reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Inc. (TVGN) reported that director Victor J. Sordillo received a grant of 75,000 shares of Common Stock on September 11, 2026. The grant is restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan and vests in three equal annual installments starting September 11, 2027, contingent on continued service. Following this award, he holds 126,539 shares directly. No Rule 10b5-1 trading plan is reported.
Tevogen Inc. (symbol: TVGN) is the issuer of record for a Form 4 filing submitted to the SEC. Feike Jeffrey L. reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Inc. (TVGN) reported that director Jeffrey L. Feike received a grant of 75,000 shares of Common Stock as restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan on September 11, 2026. The award vests ratably in three equal annual installments starting September 11, 2027, contingent on continued service, bringing his direct holdings to 131,435 shares. No Rule 10b5-1 trading plan is reported.